Venus gets European patent for antibiotic drug

The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required

Drug major  Venus Remedies Tuesday said its research arm Venus Medicine Research Centre has received patent for its antibiotic product 'VRP008' from European Patent Office (EPO).

The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required, Panchkula-based company said in a statement issued here today.

"Once launched, VRP008 (research code for this Antibiotic Adjuvant Entity) will be one of the best solutions for ICU infections," said Manu Chaudhary, Joint Managing Director cum Director Research, Venus Remedies Limited.

This product, which consists of a carbapenem and a novel amino glycoside, is the outcome of the eight years of research and it is developed by following stringent international guidelines defined for developing a new drug and has undergone for pre-clinical studies such as Acute Toxicity, Sub Acute toxicity, Intravenous, para venous toxicities as per OECD guidelines, the statement said.

At present, at least 25,000 people die each year in the European Union from infections due to 'Eskape' pathogens which are multi-drug-resistant organisms.

Infections caused by these antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days annually in Europe.

Venus has already received EU patent for its product Elores, Potentox, Vancoplus and Achnil.

Venus Remedies stock price

On June 03, 2014, Venus Remedies closed at Rs 288.95, up Rs 5.80, or 2.05 percent. The 52-week high of the share was Rs 350.00 and the 52-week low was Rs 140.00.

The company's trailing 12-month (TTM) EPS was at Rs 53.88 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 5.36. The latest book value of the company is Rs 392.69 per share. At current value, the price-to-book value of the company is 0.74.

Anda sedang membaca artikel tentang

Venus gets European patent for antibiotic drug

Dengan url

http://kebugaranhidup.blogspot.com/2014/06/venus-gets-european-patent-for.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Venus gets European patent for antibiotic drug

namun jangan lupa untuk meletakkan link

Venus gets European patent for antibiotic drug

sebagai sumbernya